文献速递肝病

美国非酒精性脂肪性肝炎相关肝硬化的患病率:国家健康与营养调查数据分析

Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
PubMed 文献 · Am J Gastroenterol · 2017-02-14

该研究分析1999-2002年和2009-2012年NHANES数据,纳入7034名成人,发现非酒精性脂肪性肝炎相关肝硬化患病率从0.072%升至0.178%,非酒精性脂肪性肝病相关进展性肝纤维化患病率从0.84%升至1.75%,肥胖、糖尿病和胰岛素抵抗也显著增加。

要点

  • 非酒精性脂肪性肝炎相关肝硬化患病率在2009-2012年组为0.178%,显著高于1999-2002年组的0.072%(P值<0.05)。
  • 非酒精性脂肪性肝病相关进展性肝纤维化患病率从1999-2002年组的0.84%升至2009-2012年组的1.75%(P值<0.001)。
  • 肥胖、糖尿病和胰岛素抵抗在2009-2012年组均显著增加(P值<0.005)。

核心结论

  • 与1999-2002年组相比,2009-2012年组的非酒精性脂肪性肝炎相关肝硬化患病率增加了2.5倍,非酒精性脂肪性肝病相关进展性肝纤维化患病率增加了2倍。
  • 推测2010年美国有417,524名成人患有非酒精性脂肪性肝炎相关肝硬化,4,104,871名成人患有非酒精性脂肪性肝病相关进展性肝纤维化。
  • 作者认为这代表了重大疾病负担,并建议需要广泛的项目来识别和治疗受影响者,以及旨在控制非酒精性脂肪性肝病及其并发症负担的公共卫生努力。

研究设计与样本

  • 分析1999-2002年和2009-2012年期间获得的美国国家健康与营养调查(NHANES)数据,估计入组时年龄≥18岁受试者的非酒精性脂肪性肝炎相关肝硬化和非酒精性脂肪性肝病相关进展性肝纤维化患病率。
  • 排除病毒性肝炎、过量饮酒、天冬氨酸氨基转移酶(AST)或丙氨酸氨基转移酶(ALT)>500以及妊娠患者。
  • 共纳入1999-2002年组和2009-2012年组7034名NHANES参与者,筛查时平均年龄分别为46.2±0.59岁和47.3±0.51岁。

主要发现

  • 非酒精性脂肪性肝炎相关肝硬化患病率在2009-2012年组为0.178%(估计有417,524名美国成人患有非酒精性脂肪性肝炎相关肝硬化),显著高于1999-2002年组的0.072%(P值<0.05)。
  • 非酒精性脂肪性肝病相关进展性肝纤维化患病率在同一时期从0.84%增加至1.75%(P值<0.001),对应4,104,871名美国成人。
  • 在同一时期,肥胖(29.8% vs 36.6%)、糖尿病(8.3% vs 11.9%)和胰岛素抵抗(34.7% vs 42.1%)也显著增加(所有P值<0.005)。

关键数值与推荐

  • 肝硬化定义为AST血小板比率指数(APRI)>2且肝功能检查异常。
  • 非酒精性脂肪性肝炎相关肝硬化定义为肝硬化且至少伴有以下一项:肥胖、糖尿病、胰岛素抵抗(HOMA-IR≥3)和代谢综合征。
  • 进展性肝纤维化通过使用APRI、纤维化-4指数(FIB-4)和非酒精性脂肪性肝病纤维化评分(NFS)的成熟截断值来定义。

临床怎么用

  • 作者建议需要广泛的项目来识别和治疗受影响者,以及旨在控制非酒精性脂肪性肝病及其并发症负担的公共卫生努力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of manifestations ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), fibrosis and eventually cirrhosis. The prevalence of NAFLD has been shown to be increasing over time; however, the prevalence of NASH cirrhosis and advanced fibrosis over time has not been well studied. Estimate the changes in prevalence of NASH cirrhosis and NAFLD-associated advanced fibrosis among adults in the United States. METHODS: National Health and Nutrition Examination Survey (NHANES) data obtained during the periods from 1999-2002 and 2009-2012 were analyzed to estimate the prevalence of NASH cirrhosis and NAFLD-associated advanced fibrosis in subjects aged ≥18 years at the time of enrollment. We excluded patients with viral hepatitis, excessive alcohol consumption, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >500 and patients who were pregnant. Cirrhosis was defined by AST to platelet ratio index (APRI) >2 and abnormal liver function tests. NASH cirrhosis was defined as cirrhosis that presented with at least one of the following: obesity, diabetes, insulin resistance (HOMA-IR≥3), and metabolic syndrome. Advanced fibrosis was defined by using well-established cutoff values for APRI, fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS). Population weighted prevalence was calculated separately for two groups to account for complex sampling method of NHANES. RESULTS: A total of 7034 NHANES participants from 1999-2002 and 2009-2012 group were included with mean age of 46.2±0.59 and 47.3±0.51 years, respectively, at the time of screening. The prevalence of NASH cirrhosis was significantly higher in 2009-2012 group (0.178% with an estimated 417,524 American adults with NASH-associated cirrhosis) compared to 1999-2002 group (0.072%); P value<0.05. The prevalence of NAFLD with advanced fibrosis also increased from 0.84 to 1.75% during the same time period (P value<0.001) corresponding to 4,104,871 American adults. During these time periods, there were also significant increases in obesity (29.8 vs. 36.6%), diabetes (8.3 vs. 11.9%), and insulin resistance (34.7 vs. 42.1%); P value <0.005 for all of them. CONCLUSIONS: There has been a 2.5-fold and 2-fold increases in the prevalence of NASH cirrhosis and NAFLD-associated advanced fibrosis, respectively, in 2009-2012 compared to 1999-2002. Extrapolation of NHANES data suggests that in 2010, 417,524 in the US had NASH cirrhosis, and 4,104,871 had NAFLD-associated advanced fibrosis. This represents a major disease burden and suggests the need for widespread programs to identify and treat those affected, and public health efforts aimed at controlling the burden of NAFLD and its complications.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Am J Gastroenterol. 2017. PMID: 28195177. doi:10.1038/ajg.2017.5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。